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Abstract 
Introduction: The presence of circulating tumor cells (CTC) is an independent prognostic 
factor for progression-free survival and breast cancer related death (BRD) for patients with 
metastatic breast cancer beginning a new line of systemic therapy. The current study was 
undertaken to explore whether the presence of CTC at the time of diagnosis was associated 
with recurrence free survival (RFS) and BRD. 
Methods: In a prospective single center study, CTC were enumerated with the CellSearch 
system in 30 ml of peripheral blood of 602 patients before undergoing surgery for breast 
cancer. 97 patients had a benign tumor, 101 did not meet the inclusion criteria of which 48 
patients with DCIS, leaving 404 stage I-III patients. Patients were stratified into unfavorable 
(CTC ≥1) and favorable (CTC = 0) prognostic groups.  
Results: >1 CTC in 30 ml blood was detected in 15 (15%) benign tumors, in 9 DCIS (19%), 
in 28 (16%) stage I, 32 (18%) stage II and in 16 (31%) patients with stage III. In stage I-III 
patients 76 (19%) had >1 CTC of whom 16 (21.1%) developed a recurrence. In 328 patients 
with 0 CTC 38 (11.6%) developed a recurrence. Four year RFS was 88.4% for favorable 
CTC and 78.9% for unfavorable CTC (p =0.038). 25 patients died of breast cancer related 
causes and 11 (44%) had >1 CTC. BRD was 4,3% for favorable and 14,5% for unfavorable 
CTC (p = 0.001). In multivariate analysis >1 CTC was associated with distant disease free 
survival, but not for overall recurrence free survival. CTC, progesterone receptor and N-stage 
were independent predictors of BRD in multivariate analysis.  
Conclusions: Presence of CTC in breast cancer patients before undergoing surgery with 
curative intend is associated with an increased risk for breast cancer related death.  
Introduction 
With 1.15 million new cases each year, breast cancer is the most common form of cancer 
among women worldwide [1]. Patients with non-metastatic breast cancer are treated 
surgically with or without adjuvant therapy. Adjuvant treatments are only indicated if they 
significantly reduce the risk for recurrence. Risk assessment is of utmost importance because 
of the well-known side effects of adjuvant treatment and is being conducted by means of 
TNM- classification and differentiation grade complemented by estrogen and progesterone 
receptor status, Her2neu expression and peri-tumor vascular invasion [2-6].
 
More recent 
improvement of the risk assessment is obtained through the molecular characterization of the 
tumor and identifies patients who are predicted to obtain the most therapeutic benefit [7-15]. 
These methods identify genetic phenotypes with a higher likelihood for micro metastasis that 
can lead to disease recurrence. Detection of the actual presence of tumor cells beyond the 
primary tumor is preferred, but may not be sufficient, as one cannot distinguish between 
dormant tumor cells and those giving rise to recurrence of the disease [16, 17]. The presence 
of micrometastases in bone marrow of breast cancer patients is associated with an increased 
risk for disease recurrence and death [18, 19]. Detection bone marrow micrometastasis has 
however not been adapted in standard in clinical practice [20]. A more attractive approach for 
the detection of the presence of tumor cells beyond the primary tumor is the detection of 
circulating tumor cells (CTC). For CTC detection a validated method is available [21] and 
several studies have demonstrated that the presence of CTC in patients with metastatic breast 
cancer is associated with a significantly shorter progression free and overall survival [22-29]. 
In these studies CTC can be found in ~70% of metastatic breast cancer patients. Before 
receiving neoadjuvant therapy for breast cancer the frequency in which CTC are detected is 
significantly lower (~20%), and their presence was associated with a significant risk for 
recurrence [30]. The purpose of this study is to examine the frequency of CTC in non-
metastatic breast cancer and determine whether their presence is associated with an increased 
recurrence rate or breast cancer related death.  
 
Materials and methods 
Study design 
In this single blind prospective study 602 patients were enrolled before surgery for a breast 
tumor with curative intend. To increase the sensitivity 30 ml of blood was drawn in all 
patients into four CellSave Preservative tubes (Veridex, Raritan, NJ) before surgery to 
measure CTC. Patients who were 18 years or older, had an ECOG performance status of 0 or 
1, and clinical stage I-III breast cancer were included in the study. Patients who were found to 
have a benign tumor after histological analysis of the removed tumor were placed in a control 
group. Patients with the following characteristics were excluded: ductal carcinoma in situ 
(DCIS), other malignancies at the time of inclusion or within 5 years prior to inclusion except 
skin malignancy other then melanoma or cervix carcinoma in situ, patients with stage IV 
breast cancer at inclusion, male breast cancer. All patients were treated in accordance with 
Dutch national guidelines [31]. According to these guidelines, adjuvant systemic treatment 
(hormonal therapy or chemotherapy) is indicated in node positive patients, node negative 
patients younger then 35 except those with a grade I tumor  1 cm, patients of 35 years and 
older with a tumor larger then 1 cm and patients older then 35 except those with a grade I  
(and grade II until 2010) between 1 and 2 cm. Chemotherapy was advised till 70 years 
followed by hormonal therapy. Adjuvant online was used to calculate survival increase due to 
chemotherapy and if this was found insignificant chemotherapy was omitted. During the 
study the chemotherapy regimen was changed from anthraclines based to regimens that also 
included taxanes. Trastuzumab treatment was given 1 year. There was no difference in 
treatment between CTC positive and CTC negative patients since treating physicians were 
blinded for CTC results. Follow-up was also in accordance with these guidelines: every three 
months in the first year with a yearly mammogram, every six months in the second year with 
a yearly mammogram, once a year from 3-5 years with mammogram. After five years, all 
patients younger than 60 were seen yearly with a mammogram. For patients older than 60 this 
was once every two years. The ethics board of Medisch Spectrum Twente, Enschede, the 
Netherlands approved the study protocol and all patients provided informed consent. We 
expected that 25% of patients would have CTC and a recurrence rate of 10% in the CTC 
negative group and 20 % in the CTC positive group. For 80% power we calculated a sample 
size of 500 patients. A minimal follow-up period of six months was chosen. Body Mass 
Index was not captured and thus not considered in our analysis. 
CellSearch system 
The CellSearch system (Veridex, Raritan NJ) was used to measure CTC. Four 7.5ml aliquots 
of each patient were analyzed within 72 hours after blood draw. This system 
immunomagnetically enriches CTC from 7.5 ml of blood targeting the epithelial cell 
adhesion molecules (EpCAM). The enriched cells are labeled with the nucleic acid dye 4’,6-
diaminodino-2-phenylindole (DAPI) and antibodies specific for leukocytes (CD45) labeled 
with Allophycocyan (APC) and specific for epithelial cells (cytokeratin 8, 18, 19) labeled 
with Phycoerythrin (PE). Images of CTC candidates were captured by a semi-automatic 
magnetic fluorescence microscope and presented to experienced operators for classification 
as CTC when the cells were larger than 4 m, expressed cytokeratin and lacked CD45 [21]. 
The operators were blinded to the clinical status of the patient. 
Statistical analysis 
Two databases were created, one with the results of the CTC analysis, patient ID and 
inclusion date and one with the clinical data from the patient charts both were merged at the 
time of the analysis at the hospital. The following clinical data were included: age, 
menopausal status, tumor stage on basis of pTNM classification, Estrogen/Progesterone 
receptor status, Her2Neu receptor status, differential grade of the tumor based on the Bloom 
Richardson method, adjuvant treatment, date of recurrence if occurred, location of recurrence 
(local vs distant), date of breast cancer associated death or non breast cancer associated death. 
ER and PR positivity was defined at 10% or more. Her2Neu positivity was defined as 3+ of 
2+ with confirmation. The time until recurrence was defined as the time between date of 
inclusion and the date on which the recurrence was objectified with an appropriate diagnostic 
test. Follow-up time was defined as the time between inclusion date and the date of the last 
check-up. Patients with no objectified recurrence at the end of follow-up were considered free 
of recurrence. SPSS (Somers, NY) was used for statistical analysis. Factors, which have 
influence on recurrence, distant disease free survival and breast cancer related survival, were 
identified and placed in a multivariate logistic regression model to identify independent 
predictors of recurrence, distant recurrence and breast cancer related death. In these models 
all univariate significant variables were included and after step by step elimination of the 
least significant variable while observing less than 10% change in regression coefficient, a 
final model was reached for both recurrence and breast cancer related death. Kaplan-Meier 
curves were generated for recurrence free survival and breast cancer related death. The log-
rank test was used to compare patients with and without CTC. For categorical variables the 
chi-square test was used. The Mann-Whitney U test was used to compare continuous 
variables. A p-value smaller then 0.05 was used to indicate a significant difference. All tests 
are two-sided. 
 
Results 
Patient characteristics 
Six hundred and two patients were recruited for the study between September 2003 and 
January 2009. This included 404 patients with stage I-III breast cancer. Their age ranged 
from 29-90 years (mean and median of 59). Ninety-seven were found to have a benign breast 
tumor and were placed in a control group. Hundred and one patients were excluded; 48 with 
DCIS, 42 due to insufficient data, 5 with unreliable CTC measurements, 4 patients turned out 
to have stage IV breast cancer at inclusion, one patient was male, and in one patient there was 
no known primary tumor. Demographics and baseline characteristics of the included patients 
are shown in Table 1. 84.7% of patients were ER positive and 71.8% were PR positive, but 
only 47.5% of patients received adjuvant hormonal therapy in accordance with Dutch 
national guidelines, which shows that our study includes a large group of patients with 
relative favorable characteristics. 27 of 81 Her2 positive patients received adjuvant treatment 
with trastuzumab. Adjuvant treatment with Trastuzumab was started at our hospital at the end 
of 2005. 
CTC 
The prevalence of CTC in the patients enrolled in the study is shown in Table 2. Patients are 
grouped as those that met the inclusion criteria i.e. stage I, II, or III disease, those with benign 
disease that served as the control group and the patients with DCIS that were excluded from 
any further analysis. In addition the prevalence of CTC in patients with stage I, II, and III 
disease are provided separately.  
Association between presence of CTC, disease recurrence and survival 
A total of 54 patients developed disease recurrence during follow up. Of the 76 patients with 
CTC, 16 (21.1%) developed a recurrence compared to 38 of 328 (11,6%) patients without 
CTC (p=0.029). The 4-years RFS is shown in Figure 1A, patients without CTC had a RFS of 
88.4% and for patients with CTC this was 78.9% (log-rank p= 0.038). Time to recurrence 
ranged from 6 till 90 months. 11 patients had a recurrence within one year of inclusion. In 
accordance with Dutch National Guidelines a Chest X-ray or CT scan, ultrasound of the liver 
and bone scan were performed in patients with stage III breast cancer prior tot surgery, but 
not in patients with stage I and II breast cancer. During follow-up a total of 34 patients died 
from which 25 died of breast-cancer related causes. The nine patients that died of other 
causes were not included in survival analysis, so that only breast cancer related death is 
analyzed. Eleven of the 25 patients (40%) that died of breast cancer related causes had CTC 
(44%) in contrast to 65 of the 328 patients (20%) with no CTC (log-rank p=0.001). BRD is 
shown in Figure 1B. Of the patients without CTC 4.3% died due to breast cancer related 
causes. In the group of patients with CTC this was 14.5% (log-rank p= 0.001). Time till death 
ranged from 6 to 89 months. All 25 patients who died were also included in the recurrence 
group. 
Univariate analysis for disease recurrence and survival 
The significance of stage, histology, differentiation, menopausal status, age, ER, PR and 
Her2/neu status, adjuvant therapy and CTC for RFS and BRD is shown in Table 1. T-stage, 
N-stage, overall stage, differential grade, ER status, PR status, Her2neu status and CTC were 
significant for RFS and BRD. For CTC a cut off value of 1 or more CTC was chosen. If 
similar analyses are performed with higher cut off values then CTC is no longer significant. 
This is probably due to the small number of patients that had 2 or more CTC. 
Multivariate analysis for disease recurrence and survival 
A multivariate analysis was performed for RFS in which all univariate significant factors 
were included (Table 1). After stepwise exclusion of the non-significant variables the final 
model is shown in Table 3. This shows that T-stage and differential grade are independent 
prognostic factors for recurrence, but that pre-operative presence of CTC is not (p=0,155). 
However if patients with local recurrence are excluded and only patients with distant 
recurrence are included in the analysis (n=41), then pre-operative presence of CTC is an 
independent prognostic factor (p=0,015) (Table 4).  For BRD the final model is shown in 
Table 5. This shows that CTC together with a negative progesterone receptor status and N-
stage are independent predictors for death due to breast cancer related causes. 
 
Discussion 
Improvement of the success rate of cancer therapy requires accurate selection of patients that 
will benefit from certain therapies. However, despite the array of biomarkers some low-risk 
patients will die from distant metastasis, whereas some high-risk patients will survive for 
decades. Although risk profile based on biomarkers can help to improve the ability to 
discriminate between low and high-risk patients, accurate detection whether or not the tumor 
has actually already disseminated will be preferred. Micro-metastasis in the bone marrow at 
diagnosis is detected in ~30% of breast cancer patients, their presence is independent of 
disease stage and is associated with an increased risk for disease recurrence [18, 19]. 
Screening for occult metastatic tumor cells in the bone marrow has however not been 
included as standard clinical routine [20]. Reasons are that it is regarded as too invasive and 
no validated methods are available to reliably enumerate disseminated tumor cells routinely 
in clinical laboratories. Detection of tumor cells in the blood is an attractive alternative as a 
validated method is available and the presence of CTC in breast cancer patients with 
metastatic disease has shown to be an independent prognostic factor for progression free and 
overall survival [22, 28, 29]. The frequency of CTC is however low and only 52% of patients 
starting first line chemotherapy have 5 or more CTC in 7.5 ml of blood [23].  In patients prior 
to pre-neoadjuvant chemotherapy and definitive surgery the frequency is even lower and 1 or 
more CTC were detected in 7.5 ml of blood in 23-24% of these patients [29, 32]. In the 
ongoing German SUCCESS-study 21% of patients at primary diagnosis of breast cancer 1 or 
more CTC were detected in 23 ml of blood [33, 34]. In this study four 7.5ml aliquots of blood 
from four blood collection tubes were investigated for the presence of CTC to increase the 
sensitivity of CTC detection with the FDA cleared CellSearch CTC test. The fourfold 
increase in blood volume was chosen as a lesser increase in blood volume was not likely to 
provide sufficient benefit [35]. A recent study suggest that this blood volume is still not 
sufficient to detect intact nucleated, EpCAM+, Cytokeratin 8,18 or 19 +, CD45 CTC in all 
patients suggesting the need for “CTC” apheresis or in-vivo detection of CTC [36]. One or 
more CTC in 30 ml of blood were detected in 76 of the 404 (19%) patients with stage I, II, or 
III breast cancer. Of the 602 patients undergoing breast surgery 48 were diagnosed with 
DCIS and surprisingly the proportion of DCIS patients in which CTC were detected was the 
same (19%) as in stage I and II cancer. The percentage of patients with detectable CTC was 
lower (15%) in the 97 patients with benign disease. In the control group from the original 
studies in metastatic breast cancer patients 8% of patients with benign breast tumors and 4% 
of healthy females had 1 or more CTC in 7.5 ml of blood [21, 22]. These observations are in 
line with the observations in this study and raise the question why a higher CTC background 
is observed in patients with benign disease as compared to healthy controls. Still for the 
identification of patients with cancer the specificity of the CTC test at this low number needs 
to be improved.  Some improvement can be obtained by elimination of the variation between 
operators in assigning the identified objects as CTC [35]. Although automation of the CTC 
assignment can eliminate this error it does not imply that the correct CTC definition is used 
[37]. Further confirmation will be needed to confirm that the events identified as CTC at this 
low frequency are indeed tumor cells. Technology to detect genetic abnormalities associated 
with cancer in CTC detected by the CellSearch system has recently been demonstrated [38]. 
Even though a background was observed in the control group the presence of CTC in 30 ml 
of pre-operatively drawn blood of patients with non-metastatic breast cancer was associated 
with a higher risk of recurrence and breast cancer related death as compared to patients 
without CTC. In multivariate logistic regression CTC were significant for death due to breast 
cancer related causes, and for distant disease free survival, but not for overall recurrence free 
survival. It has to be said that patients with CTC had higher T- and N-stages then people 
without CTC and therefore a lager group of CTC positive patients then CTC negative patients 
received adjuvant systemic therapy. This will probably have lowered the number of 
recurrences and deaths in the CTC positive group more then in the CTC negative group.  
Furthermore, of all 54 patients with recurrence, 13 had a local recurrence. The observation 
that presence of CTC was only significant for patients with distant recurrences suggest that it 
is unlikely that systemic CTC’s are detected in patients with local recurrences. Our study is 
slightly underpowered since we needed 500 patients for a power of 80% but in the end only 
included 404 patients with invasive breast cancer. Inclusion was stopped due to cessation of 
funding in 2009. In this study disease recurrence was observed in 11.6% of patients in whom 
no CTC were detected in 30 ml of blood. All patients with recurrent disease must have had 
tumor cells in the blood at some time to seed the distant metastasis and considerable 
improvement of the sensitivity and specificity of CTC detection will be needed to detect CTC 
in all patients at risk for recurrence [36]. In patients in which CTC were detected 21.1% 
developed a recurrence during the follow-up period. The median follow-up was 48 months 
and a longer follow-up may have increased this percentage. This however will not obliterate 
the specificity issue, as it is clear that the specificity of the CTC assay will need to be 
increased to assure that the detected objects are indeed cancer cells. The specificity of CTC 
detection was brought to light by the present study through the inclusion of patients with 
DCIS and benign breast disease in a completely blinded fashion in contrast to other CTC 
studies using the CellSearch system for the enumeration of CTC in the early disease setting in 
which no such controls were included [29, 32-34].  
 Moreover one would like to discriminate between dormant, viable and tumor cells that have 
metastatic potential. Larger blood volumes, alternative phenotypes, additional criteria and 
increase in recovery of CTC are all avenues that can be pursuit to increase the sensitivity of 
CTC detection.  
 
Conclusions 
Presence of CTC in breast cancer patients before undergoing surgery with curative intend is 
associated with an increased risk for breast cancer related death and distant disease free 
survival, but not for overall recurrence free survival. 
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Figure 1. Kaplan-Meier curves of recurrence free survival (Panel A) and breast cancer 
related death (Panel B) of 404 patients with stage I, II and III breast cancer. Patients 
were divided into those with 0 CTC detected in 30ml of blood and those with 1 or more CTC 
in 30 ml of blood. 
Table 1. Patient characteristics, demographics and relation to RFS en BRD. 
 n % RFS
1
 (p) BRD
2
 (p)  n % RFS (p) BRD (p) 
T stage     0.003 0.001 Ad chemo TX
4
     0.201 0.759 
 T1 229 56.7    Yes 150 37.1    
 T2 155 38.4    No 254 62.9     
 T3 12 3.0    Ad rad TX
5
   0,851 0.906 
 T4 8 2.0     Yes 295 73.0    
N stage     0.036 0.001 No 109 27.0     
 N0 261 64.6    Ad hor TX
6
     0,921 0.644 
 N1 99 24.5    Yes 192 47.5    
 N2 42 10.4    No 212 52.5     
 N3 2 0.5     Age Continuous 0.905 0.335 
Stage     0.008 0.001 Menopausal status     0.541 0.773 
 I 178 44.1    Pre 119 29.5    
 IIA 122 30.2    Post 212 52.5     
 IIB 53 12.3    CTC   0.029 0.001 
 IIIA 40 10.4    Yes 76 18.8    
 IIIB 9 1.7    No 328 81.2    
 IIIC 2 0.5     Recurrence          
Histology     0.933 0.440 Yes 54 13.4    
 Lobular 44 10.9    No  350 86.6    
 Ductal 341 84.4    Mortality         
 Other 19 4.7     Yes 34 8.4    
Differentiation   <0.001 <0.001 No 370 19.6    
 I 98 24.3    BC mortality
7
         
 II 185 45.8    Yes 25 6.2    
 III 121 30.0    No 379 93.8    
ER
1
     0.029 <0.001 Follow up         
Pos 342 84.7    min 6 months    
Neg 62 15.3     max 90 months    
PR
2
     0.061 0.001 mean 48.6 months    
Pos 290 71.8    median 48 months     
Neg 114 28.2          
Her2/neu
3
     0.024 0.010      
Pos 81 20.0         
Neg 323 80.0          
1. Estrogen receptor status. 2. Progestrone receptor status. 3. Her2/neu receptor status. 4. 
Adjuvant chemotherapy. 5. Adjuvant radiation therapy. 6. Adjuvant hormonal therapy. 7. 
Breast cancer related mortality. 
Table 2. Prevalence of circulating tumor cells. 
 Stage I-III Stage I Stage II Stage III DCIS Benign 
 n=404 n=178 n=175 n=51 n=48 n=97 
CTC n % n % n % n % n % n % 
0 328 81.2 150 84.3 143 81.7 35 68.6 39 81.3 82 84.5 
>1 76 18.8 28 15.7 32 18.2 16 31.3 9 18.7 15 15.4 
             
1 48 11.9 20 11.2 22 12.6 6 11.8 3 6.3 12 12.4 
2 5 1.2 1 0.6 3 0.6 1 2.0 2 4.2 1 1.0 
3 6 1.5 2 1.1 1 0.6 3 5.9 0 0 0 0 
4 5 1.2 1 0.6 1 0.6 3 5.9 1 2,1 0 0 
>4 12 3.0 4 2.2 5 2.9 3 5.9 3 6.3 2 2.1 
Table 3. Final Model of Multivariate Cox Regression Analysis for prediction of Recurrence 
Free Survival among Univariately Significant Parameters. 
Parameter HR 95% CI p 
CTC 0 vs > 1 1.63 0.83- 3.19 0.155 
Differentiation grade    
I 1.00   0.003   
II 2.56 0.84- 7.78 0.097   
III 5.49 1.82-16.54 0.003 
T-Stage    
1 1.00    0.038   
2 1.88 1.00- 3.55 0.050 
3+4 3.38 1.14-10.00 0.028 
Table 4. Final Model of Multivariate Cox Regression Analysis for prediction of Distant 
disease Free Survival among Univariately Significant Parameters. 
Parameter HR 95% CI p 
CTC 0 vs > 1 2.56 1.20 - 5.46 0.015 
ER pos vs neg 3.71 1.72 – 8.06 0.010 
T-Stage    
1 
2 
3+4 
1.00 
2.02 
4.24 
 
0.94 – 4.37 
1.22 – 14.77 
0.050 
0.072 
0.023 
N-Stage    
0 
1 
2+3 
1.00 
3.18 
2.58 
 
1.43 – 7.09 
0.94 – 7.07 
0.014 
0.005 
0.065 
Table 5. Final Model of Multivariate Cox regression analysis for prediction of BRD. 
Parameter HR 95% CI p 
CTC 0 vs > 1 3.47 1.36-  8.83 0.009       
PR neg vs pos 3.11 1.28-  7.56 0.012 
N-Stage    
0 1.00    0.001 
1 6.83 2.529-18.463 <0.001 
2+3 3.19 0.908-11.229 0.070 
 
 

